Literature DB >> 20233882

Glutamine synthetase immunostaining correlates with pathologic features of hepatocellular carcinoma and better survival after radiofrequency thermal ablation.

Barbara Dal Bello1, Laura Rosa, Nicoletta Campanini, Carmine Tinelli, Francesca Torello Viera, Gioacchino D'Ambrosio, Sandro Rossi, Enrico M Silini.   

Abstract

PURPOSE: Activation of the wnt pathway identifies a subgroup of hepatocellular carcinomas (HCC) with specific epidemiologic and genetic profiles. Wnt activation is predicted by mutation and/or nuclear translocation of beta-catenin and by glutamine synthetase (GS) immunoreactivity. We investigated whether GS staining associates with specific pathologic features of HCC and with survival after radiofrequency thermal ablation. EXPERIMENTAL
DESIGN: Monoistitutional retrospective-prospective study in a tertiary hospital setting. Two hundred and seven cirrhotics (mean age, 70 years; 63% males, 82.1% hepatitis C virus positive) with early HCC were consecutively treated with radiofrequency thermal ablation (RFTA). Mean tumor size was 2.7 cm; 20.3% of patients had multiple nodules; and median follow-up was 36 months with 54.6% overall mortality. Tumor samples were mainly obtained by biopsy (92,5%) and examined by H&E and immunostaining for beta-catenin and GS. Main outcome measures were overall and tumor-specific mortality by Kaplan-Meier analysis and Cox proportional hazard models corrected for competing risks.
RESULTS: Ninety-one patients (43.9%) had GS-positive HCCs by immunostaining. These tumors had larger size (P = 0.012) and characteristic histology (low grade, pseudoacini, hydropic changes, bile staining, lack of steatosis, and fibrosis). Other clinical or treatment variables were similar between groups. Variables correlating with tumor-specific and overall mortality by univariate analysis were tumor recurrence, advanced disease, posttreatment alpha-fetoprotein levels, and GS staining. Yearly, overall mortality rate was lower in GS-positive patients (12.4 versus 20% yearly; P = 0.006). By multivariate analysis, GS immunostaining correlated with reduced specific (hazard ratio, 0.58; 95% confidence interval, 0.34-0.97) and overall mortality (hazard ratio, 0.62; 95% confidence interval, 0.40-0.96).
CONCLUSIONS: Standard histology and GS status identify a HCC subset with distinct clinical and pathologic features. Copyright 2010 AACR.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20233882     DOI: 10.1158/1078-0432.CCR-09-1978

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  35 in total

1.  β-catenin alteration is rare in hepatocellular carcinoma with steatohepatitic features: immunohistochemical and mutational study.

Authors:  Sumiyo Ando; Junji Shibahara; Akimasa Hayashi; Masashi Fukayama
Journal:  Virchows Arch       Date:  2015-08-27       Impact factor: 4.064

Review 2.  Beta-catenin signaling, liver regeneration and hepatocellular cancer: sorting the good from the bad.

Authors:  Kari Nichole Nejak-Bowen; Satdarshan P S Monga
Journal:  Semin Cancer Biol       Date:  2010-12-21       Impact factor: 15.707

3.  A murine model for non-alcoholic steatohepatitis showing evidence of association between diabetes and hepatocellular carcinoma.

Authors:  Masato Fujii; Yuichiro Shibazaki; Kyoko Wakamatsu; Yutaka Honda; Yusuke Kawauchi; Kenji Suzuki; Somasundaram Arumugam; Kenichi Watanabe; Takafumi Ichida; Hitoshi Asakura; Hiroyuki Yoneyama
Journal:  Med Mol Morphol       Date:  2013-02-22       Impact factor: 2.309

Review 4.  Predicting recurrence following radiofrequency percutaneous ablation for hepatocellular carcinoma.

Authors:  Nathalie Ganne-Carrié; Jean-Charles Nault; Marianne Ziol; Gisèle N'Kontchou; Pierre Nahon; Véronique Grando; Valérie Bourcier; Sandrine Barge; Michel Beaugrand; Jean-Claude Trinchet; Olivier Seror
Journal:  Hepat Oncol       Date:  2014-12-11

Review 5.  β-Catenin Signaling and Roles in Liver Homeostasis, Injury, and Tumorigenesis.

Authors:  Satdarshan Pal Monga
Journal:  Gastroenterology       Date:  2015-03-05       Impact factor: 22.682

6.  Glutamine synthetase expression as a valuable marker of epilepsy and longer survival in newly diagnosed glioblastoma multiforme.

Authors:  Anna Rosati; Pietro Luigi Poliani; Alice Todeschini; Manuela Cominelli; Daniela Medicina; Marco Cenzato; Edda Lucia Simoncini; Stefano Maria Magrini; Michela Buglione; Salvatore Grisanti; Alessandro Padovani
Journal:  Neuro Oncol       Date:  2013-02-14       Impact factor: 12.300

7.  Glutamine fuels a vicious cycle of autophagy in the tumor stroma and oxidative mitochondrial metabolism in epithelial cancer cells: implications for preventing chemotherapy resistance.

Authors:  Ying-Hui Ko; Zhao Lin; Neal Flomenberg; Richard G Pestell; Anthony Howell; Federica Sotgia; Michael P Lisanti; Ubaldo E Martinez-Outschoorn
Journal:  Cancer Biol Ther       Date:  2011-12-15       Impact factor: 4.742

8.  Hepatocellular carcinoma arising in adenoma: similar immunohistochemical and cytogenetic features in adenoma and hepatocellular carcinoma portions of the tumor.

Authors:  Sanjay Kakar; James P Grenert; Valerie Paradis; Nicolas Pote; Shriram Jakate; Linda D Ferrell
Journal:  Mod Pathol       Date:  2014-04-18       Impact factor: 7.842

9.  Glutamine synthetase predicts adjuvant TACE response in hepatocellular carcinoma.

Authors:  Bo Zhang; Kai Liu; Jian Zhang; Liwei Dong; Zhichao Jin; Xinji Zhang; Feng Xue; Jia He
Journal:  Int J Clin Exp Med       Date:  2015-11-15

10.  Wnt-/-β-catenin pathway signaling in human hepatocellular carcinoma.

Authors:  Jaques Waisberg; Gabriela Tognini Saba
Journal:  World J Hepatol       Date:  2015-11-18
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.